Shanghai FTZ elaborates on the general data of the biomedical sector
July 02, 2024
Technology Media and Telecom
The U.S. publishes details on "Reverse CFIUS;" Shein's London listing might face obstacles; and two of the top 10 VC deals globally involve China, with much of the funding coming from Chinese state-backed investors.
June 27, 2024Alleged receiving of kickbacks by senior executives in China could subject Adidas to Chinese, as well as German and U.S. investigations; U.S. convertible bond market is used to raise funds by Chinese big tech amid IPO restrictions; and EU tariffs may lead to localization of Chinese EV production.
June 21, 2024Philip Qu and Qiuchen Wang from TransAsia Lawyers analyze a pioneering approach to regulating cross-border data transfers recently adopted in one of Shanghai's free trade zones
June 12, 2024Apple wins antitrust case in China over app store fees; Temu is now subject to stricter EU online content rules; and Record Chinese investments flow into Mexico and Vietnam amid Western trade tensions.
June 06, 2024Shanghai FTZ elaborates on the general data of the public fund sector
June 05, 2024Fang Jianwei, Lv Chao and Yuan Chenhao of Zhong Lun Law Firm in Shanghai explain the background and impact – including on multinational companies – of a set of new rules governing the local production of imported drugs
June 03, 2024Western companies are investing in Chinese biotech even amid continued geopolitical tension between China and the West and decreasing appetite for foreign investment in China; Two lithium battery part manufacturers, Capchem and Kedaliplan, plan to build factories in the U.S. to avoid hefty lithium battery tariffs; and Chinese pharma firm Asymchem to take over U.K. Pfizer plant.
May 29, 2024Shanghai FTZ expedites cross-border transfer of specified data; CBP investigation finds no substantial evidence of evasion by CIE; and Another Chinese EV SPAC merger is in the pipeline but EU tariffs threaten the business.
May 23, 2024Charles Wu of Clyde & Co describes the current regulatory state of China's investment market, for private equity investors, including the much anticipated recent clarity provided by key regulators as well as potential pitfalls to avoid
May 22, 2024
